ALNY insider buying and SEC filings, explained
Alnylam Pharmaceuticals, Inc. · CIK 1178670
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$16.1M
Planned sales (10b5-1)
$27.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 2, 2026 | Sale | Bryan Supran (EVP, CLO and Secretary) sold 1,758 shares at $226.88 ($399K). Holdings down 12% to 12,807 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 6, 2026, 4:12 PM ET |
| Jun 1, 2026 | Planned (10b5-1) | David E. I. Pyott (Director) sold 3,830 shares at about $299.18 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 71% to 1,582 shares. | SEC filing Filed Jun 3, 2026 |
| Apr 2–6, 2026 | Planned (10b5-1) | Melissa McLaughlin (Chief Human Resources Officer) sold 3,910 shares between Apr 2 and Apr 6 at about $325.92 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 29% to 9,443 shares. | SEC filing Filed Apr 7, 2026 |
| Mar 4–5, 2026 | Planned (10b5-1) | Pushkal Garg (EVP Chief R&D) sold 4,713 shares between Mar 4 and Mar 5 at about $323.53 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 20% to 18,693 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Yvonne Greenstreet (CEO and Director) sold 2,933 shares at about $323.08 ($948K). Holdings down 3% to 95,695 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Jeffrey V. Poulton (CFO) sold 2,468 shares at about $323.08 ($797K). Holdings down 4% to 61,805 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 4, 2026 | Sale | Tolga Tanguler (EVP, Chief Commercial Officer) sold 2,309 shares at about $323.08 ($746K). Holdings down 6% to 34,297 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 6, 2026 |
| Mar 4–5, 2026 | Planned (10b5-1) | Kevin Joseph Fitzgerald (CSO & EVP, Head of Research) sold 1,291 shares between Mar 4 and Mar 5 at about $323.54 ($418K), marked as a 10b5-1 plan trade. Holdings down 6% to 20,569 shares. | SEC filing Filed Mar 6, 2026 |
| Mar 2, 2026 | Sale | Jeffrey V. Poulton (CFO) sold 2,206 shares at about $327.65 ($723K). Holdings down 3% to 64,273 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2–3, 2026 | Planned (10b5-1) | Pushkal Garg (EVP Chief R&D) sold 3,492 shares between Mar 2 and Mar 3 at about $323.63 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 13% to 23,406 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2–3, 2026 | Planned (10b5-1) | Kevin Joseph Fitzgerald (CSO & EVP, Head of Research) sold 3,250 shares between Mar 2 and Mar 3 at about $323.62 ($1.1M), marked as a 10b5-1 plan trade. Holdings down 13% to 21,860 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Tolga Tanguler (EVP, Chief Commercial Officer) sold 1,598 shares at about $327.65 ($524K). Holdings down 4% to 36,606 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Sale | Yvonne Greenstreet (CEO and Director) sold 6,799 shares at about $327.65 ($2.2M). Holdings down 6% to 98,628 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Feb 27, 2026 | Planned (10b5-1) | Pushkal Garg (EVP Chief R&D) sold 4,627 shares at about $331.34 ($1.5M), marked as a 10b5-1 plan trade. Holdings down 17% to 22,129 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 13, 2026 | Sale | Pushkal Garg (EVP Chief R&D) sold 2,242 shares at about $310.08 ($695K). Holdings down 8% to 24,848 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 13, 2026 | Sale | Yvonne Greenstreet (CEO and Director) sold 6,958 shares at about $310.08 ($2.2M). Holdings down 8% to 85,662 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 13, 2026 | Sale | Tolga Tanguler (EVP, Chief Commercial Officer) sold 1,959 shares at about $310.08 ($607K). Holdings down 6% to 31,769 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Feb 13–17, 2026 | Planned (10b5-1) | Kevin Joseph Fitzgerald (CSO & EVP, Head of Research) sold 4,000 shares between Feb 13 and Feb 17 at about $321.24 ($1.3M), marked as a 10b5-1 plan trade. Holdings down 16% to 21,264 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 13, 2026 | Sale | Jeffrey V. Poulton (CFO) sold 2,242 shares at about $310.08 ($695K). Holdings down 4% to 59,802 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 17, 2026 |
| Jan 12, 2026 | Sale | Pushkal Garg (EVP Chief R&D) sold 1,510 shares at about $362.87 ($548K). Holdings down 6% to 22,511 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 14, 2026 |
| Jan 12, 2026 | Sale | Yvonne Greenstreet (CEO and Director) sold 9,577 shares at about $362.86 ($3.5M). Holdings down 11% to 78,411 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 14, 2026 |
| Jan 12, 2026 | Sale | Jeffrey V. Poulton (CFO) sold 2,780 shares at about $362.87 ($1.0M). Holdings down 5% to 57,465 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 14, 2026 |
| Jan 12, 2026 | Sale | Tolga Tanguler (EVP, Chief Commercial Officer) sold 1,510 shares at about $362.87 ($548K). Holdings down 5% to 29,728 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Jan 14, 2026 |
| Jan 12–13, 2026 | Planned (10b5-1) | Kevin Joseph Fitzgerald (CSO & EVP, Head of Research) sold 3,800 shares between Jan 12 and Jan 13 at about $367.37 ($1.4M), marked as a 10b5-1 plan trade. Holdings down 15% to 21,264 shares. | SEC filing Filed Jan 14, 2026 |
| Nov 17, 2025 | Planned (10b5-1) | Kevin Joseph Fitzgerald (CSO & EVP, Head of Research) sold 12,128 shares at about $452.18 ($5.5M), marked as a 10b5-1 plan trade. Holdings down 36% to 21,264 shares. | SEC filing Filed Nov 19, 2025 |
| Nov 12–13, 2025 | Planned (10b5-1) | Yvonne Greenstreet (CEO and Director) sold 25,650 shares between Nov 12, 2025 and Nov 13, 2025 at about $452.75 ($11.6M), marked as a 10b5-1 plan trade. Holdings down 28% to 65,409 shares. | SEC filing Filed Nov 14, 2025 |
38 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ALNY in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.